Bio-Techne/TECH

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Bio-Techne

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Ticker

TECH

Sector

Healthcare

Trading on

NASDAQ

Industry

Life Sciences Tools and Services

Headquarters

Minneapolis, United States

Employees

3,050
Website
www.bio-techne.com

Bio-Techne Metrics

BasicAdvanced
$11B
Market cap
56.94
P/E ratio
$1.25
EPS
1.23
Beta
$0.32
Dividend rate
0.45%
Dividend yield
$11B
1.23
$0.32
4.076
2.491
23.916
24.56
24.82%
14.08%
5.58%
10.40%
56.94
9.73
5.55
21.62
44.71
0.45%
2.73%
-25.06%
10.83%
2.90%

What the Analysts think about Bio-Techne

Analyst Ratings

Majority rating from 14 analysts.
Buy

Bio-Techne Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
16.15% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$303M
11.34%
Net income
$49M
78.83%
Profit margin
16.15%
60.70%

Bio-Techne Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.00%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$0.55
$0.41
$0.40
$0.48
-
Expected
$0.55
$0.44
$0.41
$0.45
$0.50
Surprise
0.58%
-5.80%
-3.05%
6.00%
-

Bio-Techne News

AllArticlesVideos

BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES

PRNewsWire·1 month ago

BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE

PRNewsWire·1 month ago

ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing

PRNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Bio-Techne stock?

Bio-Techne (TECH) has a market cap of $11B as of July 03, 2024.

What is the P/E ratio for Bio-Techne stock?

The price to earnings (P/E) ratio for Bio-Techne (TECH) stock is 56.94 as of July 03, 2024.

Does Bio-Techne stock pay dividends?

Yes, the Bio-Techne (TECH) stock pays dividends to shareholders. As of July 03, 2024, the dividend rate is $0.32 and the yield is 0.45%. Bio-Techne has a payout ratio of 24.82% on a trailing twelve-month basis.

When is the next Bio-Techne dividend payment date?

The next Bio-Techne (TECH) dividend payment date is unconfirmed.

What is the beta indicator for Bio-Techne?

Bio-Techne (TECH) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Bio-Techne stock

Buy or sell Bio-Techne stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing